Skip to main content
. 2022 Oct 5;13:988836. doi: 10.3389/fphar.2022.988836

TABLE 5.

Summary of subgroup analysis on neurological deficit scores.

Pooled estimates No. of studies Std. MD (95% CI) p value Group p-value
Model
MCAO 15 −0.96 [−1.04, −0.89] p < 0.00001
Species 0.07
SD rats 14 −0.95 [−1.02, −0.87] p < 0.00001
Wistar rats 1 −1.20 [−1.47, −0.94] p < 0.00001
Route of administration <0.00001
i.p 11 −0.92 [−1.00, −0.85] p < 0.00001
i.v 1 −3.72 [−4.93, −2.51] p < 0.00001
i.g 1 −0.80 [−1.37, −0.22] p = 0.006
ICA 1 −5.16 [−6.48, −3.85] p < 0.00001
Dosage <0.00001
<20 mg/kg 7 −1.10 [−1.29, −0.92] p < 0.00001
20 mg/kg 5 −0.71 [−0.81, −0.62] p < 0.00001
30 mg/kg 4 −1.84 [−2.08, −1.60] p < 0.00001
>30 mg/kg 6 −1.62 [−1.76, −1.47] p < 0.00001
Administration time <0.0001
Before I/R 10 −0.93 [−1.00, −0.86] p < 0.00001
After I/R 4 −1.87 [−2.25, −1.49] p < 0.00001
Before and after I/R 1 −0.97 [−1.73, −0.22] p = 0.01
Occlusion time 0.008
60 min 1 −0.92 [−1.53, −0.31] p = 0.003
90 min 2 −1.33 [−1.66, −1.01] p < 0.00001
120 min 12 −0.95 [−1.02, −0.87] p < 0.00001

BCCAO, the bilateral common carotid arteries occlusion; MCAO, middle cerebral artery occlusion; ICA, intra-carotid artery; I/R, ischemia/reperfusion; i.g., intragastric gavage; i.p., intraperitoneal; i.v., intravenous injection; SD, Sprague-Dawley.